Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer : a single NZ centre experience

Loading...
Thumbnail Image
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Fagan, J.
Lim, R.
Garett, N.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2020-10
Supervisors
Type
Conference Contribution - Oral Presentation
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
New Zealand
Citation
Vyas, M., Fagan, J., Lim, R., & Garett, N. (2020, October). Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer: A single NZ centre experience. Paper presented at the New Zealand Society for Oncology-2020, Auckland, New Zealand.
Abstract
Objectives Metastatic Castration resistant prostate cancer (mCRPC) Metastatic Castration resistant prostate cancer (mCRPC) and PSMA Various PSMA ligands and radionuclidessuitable for labelling Lu177-PSMA and Mechanism of therapy First reported outcome for Lu177-PSMA-617 Inclusion criteria Exclusion criteria Treatment protocol Response criterion Results: Patient Characteristics Results: Therapy outcomes PSA Response Haematoxicity Quality of Life Outcomes Feedback from patients Image evaluation for therapy responses Limitations Future plan Conclusion References
Publisher
Link to ePress publication
DOI
Copyright holder
Authors
Copyright notice
All rights reserved
Copyright license